Paragon Bioservices, Inc.
Cheryl T. possesses extensive experience in quality assurance within the pharmaceutical industry, currently serving as a Quality Assurance Associate III at Paragon Bioservices, Inc. Previously, Cheryl held various positions at The Henry M. Jackson Foundation for the Advancement of Military Medicine, including Quality Assurance Manager and Senior Quality Assurance Compliance Officer, where responsibilities encompassed quality auditing, workflow management, and regulatory compliance. Prior roles at Shire Pharmaceuticals as a Senior Quality Assurance Engineer and at Atlantic Pharmaceutical Services contributed to expertise in documentation review, quality system improvement, and training development. Cheryl holds a Bachelor of Science degree in Chemistry from Virginia Tech, attained between 1988 and 1993.
Paragon Bioservices, Inc.
With deep experience in viral vector scale-up and production, Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies. When it acquired MaSTherCell, Catalent added expertise in autologous and allogeneic cell therapy development and manufacturing to position it as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent has a global cell and gene therapy network of dedicated, large-scale clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. and Europe. An experienced partner, Catalent Cell & Gene Therapy has worked with industry leaders across 70+ clinical and commercial programs.